Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BCBS Opioid Abuse Plan Requires Authorization For Scripts Longer than 30 Days

This article was originally published in The Pink Sheet Daily

Executive Summary

Blue Cross Blue Shield of Massachusetts is implementing what it believes are industry-leading policies July 1 to restrain the abuse of opioid medications among its members.

You may also be interested in...



Part D "Doctor Shopping": GAO's Remedies Find Little Buy-In From CMS

A Senate hearing examining the prevalence of “doctor shopping” by Medicare Part D enrollees revealed that CMS and the Government Accountability Office disagree on possible tools to address the issue, and perhaps more basically, who is responsible for implementing them.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.

Drug Pricing Policies Attached To Surprise Medical Billing Legislation

Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel